by John-Michael Dumais, Childrens Health Defense:
As Moderna expands its mRNA vaccine pipeline to target Epstein-Barr, shingles, cancer and autoimmune diseases, scientists warn the company’s COVID-19 shots may be suppressing immune function, reactivating latent viruses and potentially causing the very conditions their new products aim to prevent.
During its Vaccines Day Event for investors on March 28, Moderna announced progress on multiple mRNA-based vaccines and therapeutic candidates in its “pipeline.”
TRUTH LIVES on at https://sgtreport.tv/
Three vaccines targeting Epstein-Barr virus (EBV), Varicella-zoster virus (VZV, chickenpox and shingles) and Norovirus are advancing to “pivotal late-stage development,” the company said.
Moderna also announced that the U.S. Food and Drug Administration (FDA) is expected to approve its respiratory syncytial virus (RSV) vaccine mRNA-1345 for older adults. This is part of an expected $52 billion market for Moderna’s infectious disease vaccines.
“We continue to explore the application of mRNA in the potential treatment of cardiovascular and other ischemic vascular diseases,” Moderna’s website states in its product plans for therapeutic areas.
The company also is developing mRNA solutions for cancer and autoimmune diseases.
Citing the well-documented and often serious adverse reactions to the COVID-19 mRNA vaccines, some scientists and doctors said they are concerned about the dangers of existing and new mRNA formulations.
They also question whether Moderna is attempting to profit from solutions for diseases its products are causing.
Read More @ ChildrensHealthDefense.org
